Esophageal Varices
Conditions
Keywords
Fecal calprotectin, esophageal varices, liver cirrhosis
Brief summary
The goal of this cross-sectional observational study is to evaluate the accuracy of fecal calprotectin versus non-invasive scores in assessing the presence and grading of esophageal varices in Egyptian patients. Researchers will compare fecal calprotectin levels in cirrhotic patients with and without esophageal varices (EVs) and healthy subjects. researchers will also evaluate the performance of fecal calprotectin, AST to platelet ratio index (APRI) score, fibrosis-4 (FIB-4) score, albumin-bilirubin (ALBI) score, platelet-albumin-bilirubin (PALBI) score, and platelet-spleen diameter ratio (PSR) for predicting esophageal varices. Participants will undergo history-taking, clinical examination, laboratory investigations, fecal calprotectin, abdominal ultrasonography, and upper endoscopy. Endoscopic grading of esophageal varices will be done using Paquet's classification. The APRI, FIB-4, ALBI, PALBI, and PSR scores will be calculated. The performance of fecal calprotectin for predicting EVs will be compared versus other non-invasive scores.
Interventions
DIAGNOSTIC_TESTfecal calprotectin
fecal calprotectin test measures calprotectin protein in a stool sample. fecal calprotectin acts as a surrogate for gastrointestinal inflammation (e.g., inflammatory bowel disease, infectious gastroenteritis, acute appendicitis, peptic ulcer disease, coeliac disease, non-steroidal anti-inflammatory drugs (NSAID)-induced enteropathy)
Sponsors
Tanta University
Study design
Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age ≥18 years * Liver cirrhosis
Exclusion criteria
* Patients aged \< 18 years. * Inflammatory bowel disease. * Infectious gastroenteritis. * Malignancy. * Patients on proton pump inhibitors or NSAID. * Patients with spontaneous bacterial peritonitis. * Patients with hepatic encephalopathy. * Unwilling to participate in our study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| measuring fecal calprotectin level (microgram/gram) for predicting esophageal varices | through study completion, an average of 1 year |
Secondary
| Measure | Time frame |
|---|---|
| comparing fecal calprotectin versus non-invasive scores for predicting esophageal varices | through study completion, an average of 1 year |
Countries
Egypt
Contacts
Primary ContactRania M Elkafoury, MD
Backup ContactNabila A Elgazzar, MD
Outcome results
None listed